We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Identiv (INVE) to Sell Part of Its Operations to Vitaprotech
Read MoreHide Full Article
Identiv (INVE - Free Report) has entered into an agreement to sell its physical security, access card and identity reader operations and assets to Vitaprotech. The deal is anticipated to close in the third quarter of 2024.
The transaction needs approval from the Committee on Foreign Investment in the United States and the Federal Trade Commission under the Hart-Scott-Rodino Act.
Upon closing the deal, some senior executives of the company, including the CEO of INVE, Steven Humphreys, will join Vitaprotech. Kirsten Newquist will become the new CEO of Identiv following the completion of the deal.
Per the terms of the agreement, Identiv will receive $145 million in cash upon closing of the transaction, subject to customary adjustments. The company plans to use this money to concentrate on healthcare sectors and other valuable opportunities where its technologies can make a big difference.
The transaction will benefit INVE’s Healthcare and RFID business with additional funds, freeing up resources and expertise in its world-class IoT industry.
The company is also benefiting from securing successful design agreements. Its technical proficiency in intellectual property, expertise in the RFID segment and ongoing deal wins position it well in the security market.
Nevertheless, INVE is facing some headwinds from the postponement of orders in the library, packaging and supply chain sectors, causing delayed shipments.
Zacks Rank and Stocks to Consider
Currently, Identiv carries a Zacks Rank #4 (Sell). Shares of INVE have gained 9% in the past year.
The Zacks Consensus Estimate for NVIDIA’s 2024 earnings per share has been revised upward by 4 cents to $23.84 in the past seven days. Shares of NVDA have skyrocketed 231% in the past year.
The Zacks Consensus Estimate for Bill Holdings’ 2024 earnings per share has been revised 32 cents northward to $2.44 in the past 60 days. Shares of BILL have lost 16.2% in the past year.
The Zacks Consensus Estimate for Bentley Systems' 2024 earnings per share has been revised upward by 3 cents to $1.02 in the past 60 days. Shares of BSY have gained 17.7% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Identiv (INVE) to Sell Part of Its Operations to Vitaprotech
Identiv (INVE - Free Report) has entered into an agreement to sell its physical security, access card and identity reader operations and assets to Vitaprotech. The deal is anticipated to close in the third quarter of 2024.
The transaction needs approval from the Committee on Foreign Investment in the United States and the Federal Trade Commission under the Hart-Scott-Rodino Act.
Upon closing the deal, some senior executives of the company, including the CEO of INVE, Steven Humphreys, will join Vitaprotech. Kirsten Newquist will become the new CEO of Identiv following the completion of the deal.
Identiv, Inc. Price and Consensus
Identiv, Inc. price-consensus-chart | Identiv, Inc. Quote
Per the terms of the agreement, Identiv will receive $145 million in cash upon closing of the transaction, subject to customary adjustments. The company plans to use this money to concentrate on healthcare sectors and other valuable opportunities where its technologies can make a big difference.
The transaction will benefit INVE’s Healthcare and RFID business with additional funds, freeing up resources and expertise in its world-class IoT industry.
The company is also benefiting from securing successful design agreements. Its technical proficiency in intellectual property, expertise in the RFID segment and ongoing deal wins position it well in the security market.
Nevertheless, INVE is facing some headwinds from the postponement of orders in the library, packaging and supply chain sectors, causing delayed shipments.
Zacks Rank and Stocks to Consider
Currently, Identiv carries a Zacks Rank #4 (Sell). Shares of INVE have gained 9% in the past year.
Some better-ranked stocks from the broader technology sector are NVIDIA (NVDA - Free Report) , Bill Holdings (BILL - Free Report) and Bentley Systems (BSY - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for NVIDIA’s 2024 earnings per share has been revised upward by 4 cents to $23.84 in the past seven days. Shares of NVDA have skyrocketed 231% in the past year.
The Zacks Consensus Estimate for Bill Holdings’ 2024 earnings per share has been revised 32 cents northward to $2.44 in the past 60 days. Shares of BILL have lost 16.2% in the past year.
The Zacks Consensus Estimate for Bentley Systems' 2024 earnings per share has been revised upward by 3 cents to $1.02 in the past 60 days. Shares of BSY have gained 17.7% in the past year.